ABSTRACT
B PM1-030 b B Adverse drug reaction profile of drug interactions involving a protein kinase inhibitor indicated in chronic myeloid leukemia from pharmacovigilance databases b M. C. Pajiep, M. Lapeyre-Mestre and F. Despas I Centre Hospitalier Universitaire (CHU) de Toulouse, France i B Introduction: b The introduction of protein kinase inhibitors (PKIs) for chronic myeloid leukemia (CML) has considerably improved prognosis of the disease but has also demonstrated a great potential for drug-drug interactions. Service de Médecine Interne et Infectiologie, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France i B Introduction: b Despite an important drug-drug interaction, it was previously suggested the clindamycin-rifampicin combination could be used in patients with bone and joints infections (BJIs) provided clindamycin is administered by continuous infusion. Most of eligible patients to the antiviral drug can benefit from it despite the risk of drug-drug interaction. Twenty patients received clindamycin without rifampicin, 19 patients received clindamycin concomitantly with rifampicin and the remaining 85 received clindamycin successively without and with rifampicin. B Results: b Among 957 patients treated with anti-PD-1/PD-L1 during the data collection period, 686 patients were included: 430 new users of a SD regimen, 161 patients who started with SD and switched to ED regimen during follow-up, and 95 new users of an ED regimen. [Extracted from the article] Copyright of Fundamental & Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
Aims: We evaluated the knowledge, attitudes, and behaviors of residents and specialists working in tertiary healthcare institutions about drug allergy. Methods: Residents and specialist medical doctors working at a tertiary health institution were included in the study. A questionnaire consisting of questions evaluating occupational and demographic characteristics, knowledge, attitudes, and behaviors about drug allergy was prepared and administered to the participants. Result: Only 26 (21.3%) of the participants had attended any training on drug allergies. Of the participants, 73 (59.8%) felt competent in taking and interpreting an accurate allergy history for drugs. Of the participants, 107 (87.7%) knew that it is often impossible to reach a definite conclusion about drug allergy based on anamnesis alone. Only half of the participants stated that they could spare enough time for detailed anamnesis about drug allergy in their daily practice. Only 19 (15.6%) of the participants stated that they referred patients with suspected drug allergies to an allergist at a rate of 90-100%. When the answers of the assistant and specialists were compared;the proportion of respondents to the question of the most important drug classes responsible for allergic reactions, including antibiotics and aspirin/other NSAIDs (28.9% vs. 67.7%;p<.001). And the rate of those who responded corticosteroids+antihistamines+adrenaline to the question of the most recommended drug classes to treat drug allergies was found to be higher in specialist physicians (19.8% vs. 71%;p<.001). Conclusion: This cross-sectional study showed a low level of awareness, knowledge, and competency in the management of drug allergies among residents and specialists from different fields.
ABSTRACT
Background: This study aims to study the predictors and the pattern of adverse drug reactions to Covishield vaccine which is being used in the mass vaccination program of the Government of India. Methods: This cross-sectional questionnaire-based study was conducted among the dentists working as faculty in four different tertiary care centers in Jaipur city. A prevalidated questionnaire was circulated through E-mail/social media groups to all the participants. Results: A total of 574 participants fulfilled the questionnaire platform;however, six had been excluded from the study due to incompletely filled questionnaires. The remaining 568 were enrolled for the final analysis. About 296 (52.11%) were male and 272 (47.89%) were female. About 52.8% were in the age group of 31–49 years. About 87.32% of the enrolled participants had received both doses of Covishield. Most common postvaccination symptoms were fever (n = 145), local pain at injection site (n = 123), tenderness at injection site (n = 117), and fatigue (n = 91). Female gender, presence of comorbid diseases, and past coronavirus disease-19 infection were statistically significant risk factors for having adverse reactions post vaccination, P = 0.02, 0.043, and 0.0002, respectively. Conclusions: The data suggest that Covishield is well tolerated in the Indian population. Fever, local pain, tenderness at injection site, and fatigue are few commonly reported side effects. All the side effects were mild to moderate in terms of severity. [ FROM AUTHOR] Copyright of Journal of Oral Research & Review is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
We present a unique case of BP-like eruption after COVID-19 mRNA vaccine that also posed a dilemma of further suitable vaccination in a patient with platelet disorder. P15 Subacute cutaneous lupus erythematosus after COVID-19 vaccination Sarah Elyoussfi and Ian Coulson I East Lancashire NHS Trust, Blackburn, UK i Numerous cutaneous reactions have been reported secondary to COVID-19 vaccinations. COVID -19 vaccination has been rapidly rolled out and side-effects in patients with rare conditions are only becoming apparent as these patients are exposed to the vaccine. Oral Presentations O01 A paediatric case series of COVID-19-associated chilblain-like acral lesions Mehak Chadha SP 1 sp and Angela Tewari SP 2 sp SP 1 sp St Peter's Hospital, Chertsey, UK;and SP 2 sp King's College Hospital, London, UK Chilblain-like acral skin lesions are a phenomenon that has been reported during the COVID-19 pandemic, particularly in younger, asymptomatic patients. Clinicians should be aware of BP-like disease that may develop after COVID-19 mRNA vaccination. [Extracted from the article] Copyright of British Journal of Dermatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
BACKGROUND: Survey studies have found that vaccinated persons tend to report more side effects after being given information about side effects rather than benefits. However, the impact of high media attention about vaccine-related side effects on the utilization of health care is unknown. We aimed to assess whether utilization of health care services for newly vaccinated health care workers changed after media attention about fatal side effects of the AstraZeneca vaccine on March 11th, 2021, and whether changes differed by age, sex, or occupation. METHODS: We utilized individual-level data on health care use, vaccination, employment, and demographics available in the Norwegian emergency preparedness register Beredt C19. In all 99,899 health care workers in Norway who were vaccinated with AstraZeneca between February 11th and March 11th, we used an event-study design with a matched comparison group to compare the change in primary and inpatient specialist care use from 14 days before to 14 days after the information shock on March 11th, 2021. RESULTS: Primary health care use increased with 8.2 daily consultations per 1000 health care workers (95% CI 7.51 to 8.89) the week following March 11th for those vaccinated with AstraZeneca (n = 99,899), compared with no increase for the unvaccinated comparison group (n = 186,885). Utilization of inpatient care also increased with 0.8 daily hospitalizations per 1000 health care workers (95% CI 0.37 to 1.23) in week two after March 11th. The sharpest increase in daily primary health care use in the first week after March 11th was found for women aged 18-44 (10.6 consultations per 1000, 95% CI 9.52 to 11.68) and for cleaners working in the health care sector (9.8 consultations per 1000, 95% CI 3.41 to 16.19). CONCLUSIONS: Health care use was higher after the media reports of a few cases of fatal or severe side effects of the AstraZeneca vaccine. Our results suggest that the reports did not only lead vaccinated individuals to contact primary health care more, but also that physicians referred and treated more cases to specialist care after the new information.
Subject(s)
COVID-19 , Vaccines , Attention , Delivery of Health Care , Female , Humans , VaccinationABSTRACT
BACKGROUND: Dysgeusia is a prevalent qualitative gustatory impairment that may affect food intake and quality of life. The facial (VII), glossopharyngeal (IX), and vagus (X) nerves are the three cranial nerves responsible for sensing taste. Typically, dysgeusia is considered a general term for all taste disorders. In addition, dysgeusia may be a symptom of underlying systemic conditions such as diabetes mellitus, chronic kidney disease, respiratory infections, and nutritional deficiencies. Various subjective and objective diagnostic approaches are available to aid clinicians, each with its own set of benefits and drawbacks. HIGHLIGHTS: Taste impairment can lead to a lack of enjoyment while eating, food aversion, and malnutrition, resulting in a decrease in the quality of life and loss of muscle mass. Therefore, the present review aims to address the probable etiologies, diagnostic aids, and management of dysgeusia. A broad search for studies was conducted using PubMed, Web of Science, Scopus, and Google Scholar. In addition, relevant studies found in the references of the selected articles were also studied. CONCLUSION: Oral health care providers should be aware of the possible etiologies of dysgeusia, diagnostic tools, and treatment options. Accurate diagnosis of the cause of taste dysfunction has a significant impact on the management of taste impairment.
Subject(s)
Dysgeusia , Quality of Life , Awareness , Dysgeusia/diagnosis , Humans , Taste , Taste DisordersABSTRACT
OBJECTIVE: Psychiatric patients are at increased risk of contamination, morbidity, and mortality associated with COVID-19, together with potentially more pronounced adverse effects. We present and discuss the adverse effects observed in an acute psychiatric clinic that has admitted COVID-19 patients during the first three months of the pandemic in Turkey. METHODS: The COVID-19 treatment schemes were formed in accordance with the national and regional guidelines at the time of admittance, which were mainly based on the use of hydroxychloroquine and other drugs. The sample consisted exclusively of inpatients, and all patients were enrolled in the study regardless of their specific diagnosis or treatment schemes. RESULTS: 4 out of 23 patients (17.4%) had experienced adverse effects, two of which had mild hepatic enzyme elevation and one had mild sinus bradycardia. Of note is that we haven't encountered any serious complications or life-threatening events during inpatient treatment. The most emphasised adverse effect in the literature, namely QTc prolongation and ECG changes, were not observed in our sample. The adverse effects were not found to be significantly associated with patient-related factors nor dose of antipsychotic medication. CONCLUSIONS: From our point of view, non-cardiac adverse effects should not be overlooked while treating comorbid psychiatric and COVID-19 patients.KEY POINTSAcute inpatient psychiatric treatment of patients who have comorbid COVID-19 is a complex situation requiring multidisciplinary action.Adverse drug reactions, which may or not result from the interaction of psychiatric and COVID-19 treatment, should be of concern for this patient group.While there is controversy over the benefits of some of the off-label COVID-19 medications, there should also be discussion over safety and concomitant medication use.In order to be adequately prepared for future escalations of COVID-19 pandemic, psychiatric services should thoroughly evaluate their initial experience with COVID-19, including from the point of drug effectiveness and safety.